Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven N Reske

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 16, 2004
Adenovirus-delivered siRNAChangxian Shen, Sven N Reske
Cancer Biotherapy & Radiopharmaceuticals|February 17, 2006
Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysisGerhard Glatting, Sven N Reske
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2006
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?Sven N Reske, Sandra Deisenhofer
Pituitary|October 13, 2006
Functional imaging of neuroendocrine tumours with PETFelix M Mottaghy, Sven N Reske
Zeitschrift Fur Medizinische Physik|May 3, 2011
Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation studyPeter Kletting, Sven N Reske, Gerhard Glatting
European Journal of Nuclear Medicine and Molecular Imaging|September 11, 2007
[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomySven N Reske, Norbert M Blumstein, Gerhard Glatting
Physics in Medicine and Biology|October 13, 2009
Comparing time activity curves using the Akaike information criterionPeter Kletting, Thomas Kull, Sven N Reske, et al.
Anticancer Research|February 5, 2009
PTEN mutation: many birds with one stone in tumorigenesisWeijin Liu, Yonggang Zhou, Sven N Reske, et al.
Physics in Medicine and Biology|December 2, 2010
Analysing saturable antibody binding based on serum data and pharmacokinetic modellingPeter Kletting, Hady Kiryakos, Sven N Reske, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2010
Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modelingPeter Kletting, Christoph Meyer, Sven N Reske, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Methods in Molecular Biology (Clifton, N.J.)|March 16, 2004
Adenovirus-delivered siRNAChangxian Shen, Sven N Reske
Cancer Biotherapy & Radiopharmaceuticals|February 17, 2006
Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysisGerhard Glatting, Sven N Reske
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2006
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?Sven N Reske, Sandra Deisenhofer
Pituitary|October 13, 2006
Functional imaging of neuroendocrine tumours with PETFelix M Mottaghy, Sven N Reske
Zeitschrift Fur Medizinische Physik|May 3, 2011
Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation studyPeter Kletting, Sven N Reske, Gerhard Glatting
European Journal of Nuclear Medicine and Molecular Imaging|September 11, 2007
[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomySven N Reske, Norbert M Blumstein, Gerhard Glatting
Physics in Medicine and Biology|October 13, 2009
Comparing time activity curves using the Akaike information criterionPeter Kletting, Thomas Kull, Sven N Reske, et al.
Anticancer Research|February 5, 2009
PTEN mutation: many birds with one stone in tumorigenesisWeijin Liu, Yonggang Zhou, Sven N Reske, et al.
Physics in Medicine and Biology|December 2, 2010
Analysing saturable antibody binding based on serum data and pharmacokinetic modellingPeter Kletting, Hady Kiryakos, Sven N Reske, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2010
Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modelingPeter Kletting, Christoph Meyer, Sven N Reske, et al.
Pageof 9